Trial reportJournal of the American Association for Laboratory Animal Science : JAALAS2017
Pharmacokinetic Profiles of Meloxicam and Sustained-release Buprenorphine in Prairie Dogs (
Trial report in Journal of the American Association for Laboratory Animal Science : JAALAS, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Pharmacokinetics of Single-dose Subcutaneous Meloxicam Injections in Black-tailed Prairie Dogs (Journal of the American Association for Laboratory Animal Science : JAALAS · 2017Trial
- Comparative Safety and Efficacy of Extended-Release Buprenorphine Formulations for Mouse Reproductive Surgeries under Tribromoethanol.Journal of the American Association for Laboratory Animal Science : JAALAS · 2025Article
- Evaluation and comparison of pharmacokinetic profiles and safety of two extended-release buprenorphine formulations in common marmosets (Callithrix jacchus).Scientific reports · 2023Article
- Long-Acting Opioid Analgesics for Acute Pain: Pharmacokinetic Evidence Reviewed.Veterinary sciences · 2023Review
- Effects of Buprenorphine Treatment on Influenza Pathogenesis in the Ferret (Comparative medicine · 2022Article
- Injection-site Reactions to Sustained-release Meloxicam in Sprague-Dawley Rats.Journal of the American Association for Laboratory Animal Science : JAALAS · 2020Article
- Design and in vivo evaluation of a microparticulate depot formulation of buprenorphine for veterinary use.Scientific reports · 2020Article
- A Comparison of Buprenorphine, Sustained release Buprenorphine, and High concentration Buprenorphine in Male New Zealand White Rabbits.Journal of the American Association for Laboratory Animal Science : JAALAS · 2020Article
- Pharmacokinetic Profiles of Gabapentin after Oral and Subcutaneous Administration in Black-tailed Prairie Dogs (Journal of the American Association for Laboratory Animal Science : JAALAS · 2020Article
- Analgesia during Monkeypox Virus Experimental Challenge Studies in Prairie Dogs (Journal of the American Association for Laboratory Animal Science : JAALAS · 2019Article
- Preliminary Evaluation of Sustained-release Compared with Conventional Formulations of Meloxicam in Sheep (Journal of the American Association for Laboratory Animal Science : JAALAS · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we evaluated the pharmacokinetic profiles of meloxicam and sustained-release (SR) buprenorphine in prairie dogs. The 4 treatment groups were: low-dose meloxicam (0.2 mg/kg SC), high-dose meloxicam (4 mg/kg SC), low-dose buprenorphine SR (0.9 mg/kg SC), and high-dose buprenorphine SR (1.2 mg/kg SC). The highest plasma concentrations occurred within 4 h of administration for both meloxicam treatment groups. The therapeutic range of meloxicam in prairie dogs is currently unknown. However, as compared with the therapeutic range documented in other species (0.39 - 0.91 μg/mL), the mean plasma concentration of meloxicam fell below the minimal therapeutic range prior to 24 h in the low-dose group but remained above therapeutic levels for more than 72 h in the high-dose group. These findings suggest that the current meloxicam dosing guidelines may be subtherapeutic for prairie dogs. The highest mean plasma concentration for buprenorphine SR occurred at the 24-h time point (0.0098 μg/mL) in the low-dose group and at the 8-h time point (0.015 μg/mL) for the high-dose group. Both dosages of buprenorphine SR maintained likely plasma therapeutic levels (0.001 μg/mL, based on previous rodent studies) beyond 72 h. Given the small scale of the study and sample size, statistical analysis was not performed. The only adverse reactions in this study were mild erythematous reactions at injection sites for buprenorphine SR.
Indexed as
Identifiers
28315645PMC5361041W2953916459What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.